AstraZeneca profits rise despite trial issues

AstraZeneca demonstrated its continued financial strength during the first half of 2026, achieving revenues of $30.7 billion, marking a 6% increase compared to the previous year. Its core operating profits rose to $10.5 billion, an increase of 11%. The company's growth is primarily focused on the oncology and rare diseases sectors, where revenues in this area reached $25.6 billion, accounting for 44% of total sales, with a 15% growth. Despite some setbacks in clinical trials, the company reaffirmed its commitment to reaching an annual revenue target of $80 billion by 2030, noting that second-quarter profits exceeded market expectations. AstraZeneca anticipates continued growth in earnings per share in 2026, driven by ongoing demand for cancer and rare disease medications.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل